Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer.

Official registry: https://clinicaltrials.gov/study/NCT02594202 · National Cancer Institute (NCI) · enrollment listed as 3,000

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 3,000 people at Bethesda. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Primary outcome (registry wording): Collect samples for the purpose of studying the molecular mechanisms of carcinogenesis in prostate cancer

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Men only
  • how well you can do daily activities (ECOG score) of 0-2
  • PSA \> or equal to 1.0 ng/ml (for patients aged 30 - 49 years) OR
  • PSA \> or equal to 2.5 ng/ml (for patients 50 years or older) OR
  • Abnormal DRE (i.e. enlarged, asymmetric, nodular, firm or tender) OR
  • Abnormal prostate MRI finding OR
  • Family history of first degree relatives (brother or father) with prostate cancer or first-degree relatives (mother or sister) with breast or ovarian cancer

Public study contact (from the registry)

Karen K Holcomb

(240) 974-9026

karen.holcomb@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT02594202 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT02594202?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT02594202?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary